14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SAIQ vs APUS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Apimeds Pharmaceuticals US, Inc. (APUS) is the stronger overall head-to-head candidate over SAIQ (SAIQ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SAIQ carries a Unified Composite Score of 50.0/100 (HOLD) at $3.45 (N/M Forward P/E, N/A operating margin), whereas APUS carries 48.5/100 (HOLD) at $2.05 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While SAIQ currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. APUS 48.5/100 HOLD), APUS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: SAIQ trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile APUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SAIQ vs APUS. Trailing 12-month operating profitability (SAIQ N/A vs APUS 0.0%) and valuation multiples (SAIQ N/M vs APUS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SAIQ vs APUS Key Questions & Quantitative Answers
As of Nov 16, 2026, Apimeds Pharmaceuticals US, Inc. (APUS) is the stronger overall head-to-head candidate over SAIQ (SAIQ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SAIQ carries a Unified Composite Score of 50.0/100 (HOLD) at $3.45 (N/M Forward P/E, N/A operating margin), whereas APUS carries 48.5/100 (HOLD) at $2.05 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SAIQ currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. APUS 48.5/100 HOLD), APUS captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: SAIQ trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile APUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
APUS leads the Growth & Scale pillar: SAIQ posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with APUS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SAIQ generates N/A in USD-normalized revenue versus N/A for APUS. In operating R&D and SG&A reinvestment, SAIQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for APUS.
SAIQ and APUS trade at balanced relative valuation multiples. SAIQ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas APUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SAIQ (N/A ROE) versus APUS (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, SAIQ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.16β · 394% Vol realized risk). By comparison, APUS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.97β · 67% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.